Effect of Dexamethasone on the Incidence and Outcome of COVID-19 Associated Pulmonary Aspergillosis (CAPA) in Critically Ill Patients during First- and Second Pandemic Wave—A Single Center Experience

Effect of Dexamethasone on the Incidence and Outcome of COVID-19 Associated Pulmonary Aspergillosis (CAPA) in Critically Ill Patients during First- and Second Pandemic Wave—A Single Center Experience

Superinfections with <i>Aspergillus</i> spp. in patients with Coronavirus disease 2019 (CAPA: COVID-19-associated pulmonary aspergillosis) are increasing. Dexamethasone has shown beneficial effects in critically ill COVID-19 patients. Whether dexamethasone increases the risk of CAPA has...

Full description

Bibliographic Details
Main Authors: Simon Dubler, Ömer Can Turan, Karsten Daniel Schmidt, Peter-michael rath, Hedda-Luise Verhasselt, Sandra Maier, Annabell Skarabis, Thorsten Brenner, Frank Herbstreit
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Diagnostics
Subjects:
COVID-19
CAPA
<i>Aspergillus fumigatus</i>
dexamethasone
intensive care medicine
ICU
Online Access:https://www.mdpi.com/2075-4418/12/12/3049

Internet

https://www.mdpi.com/2075-4418/12/12/3049

Similar Items